Performance	O
of	O
ANTI	B:C0201487
-	I:C0201487
HCV	I:C0201487
testing	I:C0201487
in	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
according	O
to	O
HIV	O
status	I:C0458074
.	O

Performance	O
of	O
ANTI	O
-	I:C0201487
HCV	I:C0201487
testing	I:C0201487
in	O
dried	B:C3830395
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
according	O
to	O
HIV	O
status	I:C0458074
.	O

Performance	O
of	O
ANTI	O
-	I:C0201487
HCV	I:C0201487
testing	I:C0201487
in	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	B:C0036087
according	O
to	O
HIV	O
status	I:C0458074
.	O

Performance	O
of	O
ANTI	O
-	I:C0201487
HCV	I:C0201487
testing	I:C0201487
in	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
according	O
to	O
HIV	B:C0458074
status	I:C0458074
.	O

The	O
use	O
of	O
saliva	B:C0036087
and	O
dried	O
blood	I:C3830395
spots	I:C3830395
(	O
dried	O
blood	I:C3830395
spots	I:C3830395
)	O
could	O
increase	O
access	O
to	O
HCV	O
diagnosis	O
for	O
high	O
-	I:C0870646
risk	I:C0870646
populations	I:C0870646
,	O
such	O
as	O
HIV	O
-	I:C0019693
infected	I:C0019693
individuals	O
,	O
but	O
the	O
performance	O
of	O
these	O
assays	O
has	O
not	O
been	O
well	O
established	O
in	O
this	O
group	O
.	O

The	O
use	O
of	O
saliva	O
and	O
dried	B:C3830395
blood	I:C3830395
spots	I:C3830395
(	O
dried	O
blood	I:C3830395
spots	I:C3830395
)	O
could	O
increase	O
access	O
to	O
HCV	O
diagnosis	O
for	O
high	O
-	I:C0870646
risk	I:C0870646
populations	I:C0870646
,	O
such	O
as	O
HIV	O
-	I:C0019693
infected	I:C0019693
individuals	O
,	O
but	O
the	O
performance	O
of	O
these	O
assays	O
has	O
not	O
been	O
well	O
established	O
in	O
this	O
group	O
.	O

The	O
use	O
of	O
saliva	O
and	O
dried	O
blood	I:C3830395
spots	I:C3830395
(	O
dried	B:C3830395
blood	I:C3830395
spots	I:C3830395
)	O
could	O
increase	O
access	O
to	O
HCV	O
diagnosis	O
for	O
high	O
-	I:C0870646
risk	I:C0870646
populations	I:C0870646
,	O
such	O
as	O
HIV	O
-	I:C0019693
infected	I:C0019693
individuals	O
,	O
but	O
the	O
performance	O
of	O
these	O
assays	O
has	O
not	O
been	O
well	O
established	O
in	O
this	O
group	O
.	O

The	O
use	O
of	O
saliva	O
and	O
dried	O
blood	I:C3830395
spots	I:C3830395
(	O
dried	O
blood	I:C3830395
spots	I:C3830395
)	O
could	O
increase	O
access	O
to	O
HCV	B:C4288963
diagnosis	O
for	O
high	O
-	I:C0870646
risk	I:C0870646
populations	I:C0870646
,	O
such	O
as	O
HIV	O
-	I:C0019693
infected	I:C0019693
individuals	O
,	O
but	O
the	O
performance	O
of	O
these	O
assays	O
has	O
not	O
been	O
well	O
established	O
in	O
this	O
group	O
.	O

The	O
use	O
of	O
saliva	O
and	O
dried	O
blood	I:C3830395
spots	I:C3830395
(	O
dried	O
blood	I:C3830395
spots	I:C3830395
)	O
could	O
increase	O
access	O
to	O
HCV	O
diagnosis	B:C0011900
for	O
high	O
-	I:C0870646
risk	I:C0870646
populations	I:C0870646
,	O
such	O
as	O
HIV	O
-	I:C0019693
infected	I:C0019693
individuals	O
,	O
but	O
the	O
performance	O
of	O
these	O
assays	O
has	O
not	O
been	O
well	O
established	O
in	O
this	O
group	O
.	O

The	O
use	O
of	O
saliva	O
and	O
dried	O
blood	I:C3830395
spots	I:C3830395
(	O
dried	O
blood	I:C3830395
spots	I:C3830395
)	O
could	O
increase	O
access	O
to	O
HCV	O
diagnosis	O
for	O
high	B:C0870646
-	I:C0870646
risk	I:C0870646
populations	I:C0870646
,	O
such	O
as	O
HIV	O
-	I:C0019693
infected	I:C0019693
individuals	O
,	O
but	O
the	O
performance	O
of	O
these	O
assays	O
has	O
not	O
been	O
well	O
established	O
in	O
this	O
group	O
.	O

The	O
use	O
of	O
saliva	O
and	O
dried	O
blood	I:C3830395
spots	I:C3830395
(	O
dried	O
blood	I:C3830395
spots	I:C3830395
)	O
could	O
increase	O
access	O
to	O
HCV	O
diagnosis	O
for	O
high	O
-	I:C0870646
risk	I:C0870646
populations	I:C0870646
,	O
such	O
as	O
HIV	B:C0019693
-	I:C0019693
infected	I:C0019693
individuals	O
,	O
but	O
the	O
performance	O
of	O
these	O
assays	O
has	O
not	O
been	O
well	O
established	O
in	O
this	O
group	O
.	O

The	O
use	O
of	O
saliva	O
and	O
dried	O
blood	I:C3830395
spots	I:C3830395
(	O
dried	O
blood	I:C3830395
spots	I:C3830395
)	O
could	O
increase	O
access	O
to	O
HCV	O
diagnosis	O
for	O
high	O
-	I:C0870646
risk	I:C0870646
populations	I:C0870646
,	O
such	O
as	O
HIV	O
-	I:C0019693
infected	I:C0019693
individuals	B:C0237401
,	O
but	O
the	O
performance	O
of	O
these	O
assays	O
has	O
not	O
been	O
well	O
established	O
in	O
this	O
group	O
.	O

The	O
use	O
of	O
saliva	O
and	O
dried	O
blood	I:C3830395
spots	I:C3830395
(	O
dried	O
blood	I:C3830395
spots	I:C3830395
)	O
could	O
increase	O
access	O
to	O
HCV	O
diagnosis	O
for	O
high	O
-	I:C0870646
risk	I:C0870646
populations	I:C0870646
,	O
such	O
as	O
HIV	O
-	I:C0019693
infected	I:C0019693
individuals	O
,	O
but	O
the	O
performance	O
of	O
these	O
assays	B:C1510438
has	O
not	O
been	O
well	O
established	O
in	O
this	O
group	O
.	O

This	O
study	O
aims	O
to	O
evaluate	B:C0220825
HIV	O
status	I:C0458074
,	O
particularly	O
TCD4	O
(+	I:C0039215
)	I:C0039215
cell	I:C0039215
count	O
and	O
viral	O
load	I:C1168369
,	O
in	O
the	O
performance	O
of	O
anti-HCV	O
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
.	O

This	O
study	O
aims	O
to	O
evaluate	O
HIV	B:C0458074
status	I:C0458074
,	O
particularly	O
TCD4	O
(+	I:C0039215
)	I:C0039215
cell	I:C0039215
count	O
and	O
viral	O
load	I:C1168369
,	O
in	O
the	O
performance	O
of	O
anti-HCV	O
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
.	O

This	O
study	O
aims	O
to	O
evaluate	O
HIV	O
status	I:C0458074
,	O
particularly	O
TCD4	B:C0039215
(+	I:C0039215
)	I:C0039215
cell	I:C0039215
count	O
and	O
viral	O
load	I:C1168369
,	O
in	O
the	O
performance	O
of	O
anti-HCV	O
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
.	O

This	O
study	O
aims	O
to	O
evaluate	O
HIV	O
status	I:C0458074
,	O
particularly	O
TCD4	O
(+	I:C0039215
)	I:C0039215
cell	I:C0039215
count	B:C0007584
and	O
viral	O
load	I:C1168369
,	O
in	O
the	O
performance	O
of	O
anti-HCV	O
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
.	O

This	O
study	O
aims	O
to	O
evaluate	O
HIV	O
status	I:C0458074
,	O
particularly	O
TCD4	O
(+	I:C0039215
)	I:C0039215
cell	I:C0039215
count	O
and	O
viral	B:C1168369
load	I:C1168369
,	O
in	O
the	O
performance	O
of	O
anti-HCV	O
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
.	O

This	O
study	O
aims	O
to	O
evaluate	O
HIV	O
status	I:C0458074
,	O
particularly	O
TCD4	O
(+	I:C0039215
)	I:C0039215
cell	I:C0039215
count	O
and	O
viral	O
load	I:C1168369
,	O
in	O
the	O
performance	O
of	O
anti-HCV	B:C0201487
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
.	O

This	O
study	O
aims	O
to	O
evaluate	O
HIV	O
status	I:C0458074
,	O
particularly	O
TCD4	O
(+	I:C0039215
)	I:C0039215
cell	I:C0039215
count	O
and	O
viral	O
load	I:C1168369
,	O
in	O
the	O
performance	O
of	O
anti-HCV	O
testing	I:C0201487
using	O
dried	B:C3830395
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
.	O

This	O
study	O
aims	O
to	O
evaluate	O
HIV	O
status	I:C0458074
,	O
particularly	O
TCD4	O
(+	I:C0039215
)	I:C0039215
cell	I:C0039215
count	O
and	O
viral	O
load	I:C1168369
,	O
in	O
the	O
performance	O
of	O
anti-HCV	O
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	B:C0036087
.	O

A	O
total	O
of	O
961	O
individuals	B:C0237401
classified	O
as	O
HCV	O
+	I:C2748185
,	O
HIV	O
+	I:C2748218
,	O
or	O
HIV	O
/	O
HCV	O
+	I:C2748185
,	O
as	O
well	O
as	O
negative	O
controls	O
,	O
donated	O
serum	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
,	O
and	O
saliva	O
samples	I:C0438730
for	O
anti-HCV	O
testing	I:C0201487
using	O
a	O
commercial	O
enzyme	O
immunoassay	I:C0086231
.	O

A	O
total	O
of	O
961	O
individuals	O
classified	O
as	O
HCV	B:C2748185
+	I:C2748185
,	O
HIV	O
+	I:C2748218
,	O
or	O
HIV	O
/	O
HCV	O
+	I:C2748185
,	O
as	O
well	O
as	O
negative	O
controls	O
,	O
donated	O
serum	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
,	O
and	O
saliva	O
samples	I:C0438730
for	O
anti-HCV	O
testing	I:C0201487
using	O
a	O
commercial	O
enzyme	O
immunoassay	I:C0086231
.	O

A	O
total	O
of	O
961	O
individuals	O
classified	O
as	O
HCV	O
+	I:C2748185
,	O
HIV	B:C2748218
+	I:C2748218
,	O
or	O
HIV	O
/	O
HCV	O
+	I:C2748185
,	O
as	O
well	O
as	O
negative	O
controls	O
,	O
donated	O
serum	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
,	O
and	O
saliva	O
samples	I:C0438730
for	O
anti-HCV	O
testing	I:C0201487
using	O
a	O
commercial	O
enzyme	O
immunoassay	I:C0086231
.	O

A	O
total	O
of	O
961	O
individuals	O
classified	O
as	O
HCV	O
+	I:C2748185
,	O
HIV	O
+	I:C2748218
,	O
or	O
HIV	B:C2748218
/	O
HCV	O
+	I:C2748185
,	O
as	O
well	O
as	O
negative	O
controls	O
,	O
donated	O
serum	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
,	O
and	O
saliva	O
samples	I:C0438730
for	O
anti-HCV	O
testing	I:C0201487
using	O
a	O
commercial	O
enzyme	O
immunoassay	I:C0086231
.	O

A	O
total	O
of	O
961	O
individuals	O
classified	O
as	O
HCV	O
+	I:C2748185
,	O
HIV	O
+	I:C2748218
,	O
or	O
HIV	O
/	O
HCV	B:C2748185
+	I:C2748185
,	O
as	O
well	O
as	O
negative	O
controls	O
,	O
donated	O
serum	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
,	O
and	O
saliva	O
samples	I:C0438730
for	O
anti-HCV	O
testing	I:C0201487
using	O
a	O
commercial	O
enzyme	O
immunoassay	I:C0086231
.	O

A	O
total	O
of	O
961	O
individuals	O
classified	O
as	O
HCV	O
+	I:C2748185
,	O
HIV	O
+	I:C2748218
,	O
or	O
HIV	O
/	O
HCV	O
+	I:C2748185
,	O
as	O
well	O
as	O
negative	O
controls	O
,	O
donated	O
serum	B:C0229671
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
,	O
and	O
saliva	O
samples	I:C0438730
for	O
anti-HCV	O
testing	I:C0201487
using	O
a	O
commercial	O
enzyme	O
immunoassay	I:C0086231
.	O

A	O
total	O
of	O
961	O
individuals	O
classified	O
as	O
HCV	O
+	I:C2748185
,	O
HIV	O
+	I:C2748218
,	O
or	O
HIV	O
/	O
HCV	O
+	I:C2748185
,	O
as	O
well	O
as	O
negative	O
controls	O
,	O
donated	O
serum	O
,	O
dried	B:C3830395
blood	I:C3830395
spots	I:C3830395
,	O
and	O
saliva	O
samples	I:C0438730
for	O
anti-HCV	O
testing	I:C0201487
using	O
a	O
commercial	O
enzyme	O
immunoassay	I:C0086231
.	O

A	O
total	O
of	O
961	O
individuals	O
classified	O
as	O
HCV	O
+	I:C2748185
,	O
HIV	O
+	I:C2748218
,	O
or	O
HIV	O
/	O
HCV	O
+	I:C2748185
,	O
as	O
well	O
as	O
negative	O
controls	O
,	O
donated	O
serum	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
,	O
and	O
saliva	B:C0438730
samples	I:C0438730
for	O
anti-HCV	O
testing	I:C0201487
using	O
a	O
commercial	O
enzyme	O
immunoassay	I:C0086231
.	O

A	O
total	O
of	O
961	O
individuals	O
classified	O
as	O
HCV	O
+	I:C2748185
,	O
HIV	O
+	I:C2748218
,	O
or	O
HIV	O
/	O
HCV	O
+	I:C2748185
,	O
as	O
well	O
as	O
negative	O
controls	O
,	O
donated	O
serum	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
,	O
and	O
saliva	O
samples	I:C0438730
for	O
anti-HCV	B:C0201487
testing	I:C0201487
using	O
a	O
commercial	O
enzyme	O
immunoassay	I:C0086231
.	O

A	O
total	O
of	O
961	O
individuals	O
classified	O
as	O
HCV	O
+	I:C2748185
,	O
HIV	O
+	I:C2748218
,	O
or	O
HIV	O
/	O
HCV	O
+	I:C2748185
,	O
as	O
well	O
as	O
negative	O
controls	O
,	O
donated	O
serum	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
,	O
and	O
saliva	O
samples	I:C0438730
for	O
anti-HCV	O
testing	I:C0201487
using	O
a	O
commercial	O
enzyme	B:C0086231
immunoassay	I:C0086231
.	O

Sample	B:C1318073
volume	I:C1318073
was	O
modified	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
and	O
an	O
ROC	O
curve	O
was	O
used	O
for	O
cut	O
-	O
off	O
determination	O
in	O
saliva	O
.	O

Sample	O
volume	I:C1318073
was	O
modified	O
for	O
dried	B:C3830395
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
and	O
an	O
ROC	O
curve	O
was	O
used	O
for	O
cut	O
-	O
off	O
determination	O
in	O
saliva	O
.	O

Sample	O
volume	I:C1318073
was	O
modified	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	B:C0036087
,	O
and	O
an	O
ROC	O
curve	O
was	O
used	O
for	O
cut	O
-	O
off	O
determination	O
in	O
saliva	O
.	O

Sample	O
volume	I:C1318073
was	O
modified	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
and	O
an	O
ROC	O
curve	O
was	O
used	O
for	O
cut	O
-	O
off	O
determination	B:C1148554
in	O
saliva	O
.	O

Sample	O
volume	I:C1318073
was	O
modified	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
and	O
an	O
ROC	O
curve	O
was	O
used	O
for	O
cut	O
-	O
off	O
determination	O
in	O
saliva	B:C0036087
.	O

Anti-HCV	B:C0166049
sensitivities	O
were	O
greater	O
than	O
93	O
%	O
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
,	O
while	O
they	O
were	O
83.3	O
%	O
and	O
95.6	O
%	O
for	O
HCV	O
/	O
HIV	O
+	I:C2748218
individuals	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
assays	O
,	O
respectively	O
.	O

Anti-HCV	O
sensitivities	O
were	O
greater	O
than	O
93	O
%	O
using	O
dried	B:C3830395
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
,	O
while	O
they	O
were	O
83.3	O
%	O
and	O
95.6	O
%	O
for	O
HCV	O
/	O
HIV	O
+	I:C2748218
individuals	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
assays	O
,	O
respectively	O
.	O

Anti-HCV	O
sensitivities	O
were	O
greater	O
than	O
93	O
%	O
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	B:C0036087
in	O
the	O
HCV	O
+	I:C2748185
group	O
,	O
while	O
they	O
were	O
83.3	O
%	O
and	O
95.6	O
%	O
for	O
HCV	O
/	O
HIV	O
+	I:C2748218
individuals	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
assays	O
,	O
respectively	O
.	O

Anti-HCV	O
sensitivities	O
were	O
greater	O
than	O
93	O
%	O
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
in	O
the	O
HCV	B:C2748185
+	I:C2748185
group	O
,	O
while	O
they	O
were	O
83.3	O
%	O
and	O
95.6	O
%	O
for	O
HCV	O
/	O
HIV	O
+	I:C2748218
individuals	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
assays	O
,	O
respectively	O
.	O

Anti-HCV	O
sensitivities	O
were	O
greater	O
than	O
93	O
%	O
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
,	O
while	O
they	O
were	O
83.3	O
%	O
and	O
95.6	O
%	O
for	O
HCV	B:C2748185
/	O
HIV	O
+	I:C2748218
individuals	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
assays	O
,	O
respectively	O
.	O

Anti-HCV	O
sensitivities	O
were	O
greater	O
than	O
93	O
%	O
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
,	O
while	O
they	O
were	O
83.3	O
%	O
and	O
95.6	O
%	O
for	O
HCV	O
/	O
HIV	B:C2748218
+	I:C2748218
individuals	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
assays	O
,	O
respectively	O
.	O

Anti-HCV	O
sensitivities	O
were	O
greater	O
than	O
93	O
%	O
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
,	O
while	O
they	O
were	O
83.3	O
%	O
and	O
95.6	O
%	O
for	O
HCV	O
/	O
HIV	O
+	I:C2748218
individuals	B:C0237401
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
assays	O
,	O
respectively	O
.	O

Anti-HCV	O
sensitivities	O
were	O
greater	O
than	O
93	O
%	O
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
,	O
while	O
they	O
were	O
83.3	O
%	O
and	O
95.6	O
%	O
for	O
HCV	O
/	O
HIV	O
+	I:C2748218
individuals	O
for	O
dried	B:C3830395
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
assays	O
,	O
respectively	O
.	O

Anti-HCV	O
sensitivities	O
were	O
greater	O
than	O
93	O
%	O
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
,	O
while	O
they	O
were	O
83.3	O
%	O
and	O
95.6	O
%	O
for	O
HCV	O
/	O
HIV	O
+	I:C2748218
individuals	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	B:C0036087
assays	O
,	O
respectively	O
.	O

Anti-HCV	O
sensitivities	O
were	O
greater	O
than	O
93	O
%	O
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
,	O
while	O
they	O
were	O
83.3	O
%	O
and	O
95.6	O
%	O
for	O
HCV	O
/	O
HIV	O
+	I:C2748218
individuals	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
assays	B:C1510438
,	O
respectively	O
.	O

Specificity	B:C0003264
varied	O
from	O
91.7	O
%	O
to	O
100	O
%	O
using	O
saliva	O
and	O
dried	O
blood	I:C3830395
spots	I:C3830395
in	O
HIV	O
monoinfected	I:C0019693
and	O
control	O
subjects	O
.	O

Specificity	O
varied	O
from	O
91.7	O
%	O
to	O
100	O
%	O
using	O
saliva	B:C0036087
and	O
dried	O
blood	I:C3830395
spots	I:C3830395
in	O
HIV	O
monoinfected	I:C0019693
and	O
control	O
subjects	O
.	O

Specificity	O
varied	O
from	O
91.7	O
%	O
to	O
100	O
%	O
using	O
saliva	O
and	O
dried	B:C3830395
blood	I:C3830395
spots	I:C3830395
in	O
HIV	O
monoinfected	I:C0019693
and	O
control	O
subjects	O
.	O

Specificity	O
varied	O
from	O
91.7	O
%	O
to	O
100	O
%	O
using	O
saliva	O
and	O
dried	O
blood	I:C3830395
spots	I:C3830395
in	O
HIV	B:C0019693
monoinfected	I:C0019693
and	O
control	O
subjects	O
.	O

When	O
only	O
anti-HCV	B:C0166049
/	O
HCV	O
RNA	I:C0855842
+	I:C0855842
serum	O
samples	I:C1550100
,	O
that	O
is	O
,	O
true	O
positives	O
,	O
were	O
considered	O
,	O
the	O
sensitivities	O
were	O
98.3	O
%	O
and	O
100	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
and	O
91.6	O
%	O
and	O
94.8	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

When	O
only	O
anti-HCV	O
/	O
HCV	B:C0855842
RNA	I:C0855842
+	I:C0855842
serum	O
samples	I:C1550100
,	O
that	O
is	O
,	O
true	O
positives	O
,	O
were	O
considered	O
,	O
the	O
sensitivities	O
were	O
98.3	O
%	O
and	O
100	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
and	O
91.6	O
%	O
and	O
94.8	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

When	O
only	O
anti-HCV	O
/	O
HCV	O
RNA	I:C0855842
+	I:C0855842
serum	B:C1550100
samples	I:C1550100
,	O
that	O
is	O
,	O
true	O
positives	O
,	O
were	O
considered	O
,	O
the	O
sensitivities	O
were	O
98.3	O
%	O
and	O
100	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
and	O
91.6	O
%	O
and	O
94.8	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

When	O
only	O
anti-HCV	O
/	O
HCV	O
RNA	I:C0855842
+	I:C0855842
serum	O
samples	I:C1550100
,	O
that	O
is	O
,	O
true	O
positives	O
,	O
were	O
considered	O
,	O
the	O
sensitivities	O
were	O
98.3	O
%	O
and	O
100	O
%	O
for	O
dried	B:C3830395
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
and	O
91.6	O
%	O
and	O
94.8	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

When	O
only	O
anti-HCV	O
/	O
HCV	O
RNA	I:C0855842
+	I:C0855842
serum	O
samples	I:C1550100
,	O
that	O
is	O
,	O
true	O
positives	O
,	O
were	O
considered	O
,	O
the	O
sensitivities	O
were	O
98.3	O
%	O
and	O
100	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	B:C0036087
,	O
respectively	O
,	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
and	O
91.6	O
%	O
and	O
94.8	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

When	O
only	O
anti-HCV	O
/	O
HCV	O
RNA	I:C0855842
+	I:C0855842
serum	O
samples	I:C1550100
,	O
that	O
is	O
,	O
true	O
positives	O
,	O
were	O
considered	O
,	O
the	O
sensitivities	O
were	O
98.3	O
%	O
and	O
100	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HCV	B:C2748185
+	I:C2748185
group	O
and	O
91.6	O
%	O
and	O
94.8	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

When	O
only	O
anti-HCV	O
/	O
HCV	O
RNA	I:C0855842
+	I:C0855842
serum	O
samples	I:C1550100
,	O
that	O
is	O
,	O
true	O
positives	O
,	O
were	O
considered	O
,	O
the	O
sensitivities	O
were	O
98.3	O
%	O
and	O
100	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HCV	O
+	I:C2748185
group	B:C1257890
and	O
91.6	O
%	O
and	O
94.8	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

When	O
only	O
anti-HCV	O
/	O
HCV	O
RNA	I:C0855842
+	I:C0855842
serum	O
samples	I:C1550100
,	O
that	O
is	O
,	O
true	O
positives	O
,	O
were	O
considered	O
,	O
the	O
sensitivities	O
were	O
98.3	O
%	O
and	O
100	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
and	O
91.6	O
%	O
and	O
94.8	O
%	O
for	O
dried	B:C3830395
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

When	O
only	O
anti-HCV	O
/	O
HCV	O
RNA	I:C0855842
+	I:C0855842
serum	O
samples	I:C1550100
,	O
that	O
is	O
,	O
true	O
positives	O
,	O
were	O
considered	O
,	O
the	O
sensitivities	O
were	O
98.3	O
%	O
and	O
100	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
and	O
91.6	O
%	O
and	O
94.8	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	B:C0036087
,	O
respectively	O
,	O
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

When	O
only	O
anti-HCV	O
/	O
HCV	O
RNA	I:C0855842
+	I:C0855842
serum	O
samples	I:C1550100
,	O
that	O
is	O
,	O
true	O
positives	O
,	O
were	O
considered	O
,	O
the	O
sensitivities	O
were	O
98.3	O
%	O
and	O
100	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
and	O
91.6	O
%	O
and	O
94.8	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HIV	B:C2748218
/	O
HCV	O
+	I:C2748185
group	O
.	O

When	O
only	O
anti-HCV	O
/	O
HCV	O
RNA	I:C0855842
+	I:C0855842
serum	O
samples	I:C1550100
,	O
that	O
is	O
,	O
true	O
positives	O
,	O
were	O
considered	O
,	O
the	O
sensitivities	O
were	O
98.3	O
%	O
and	O
100	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
and	O
91.6	O
%	O
and	O
94.8	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HIV	O
/	O
HCV	B:C2748185
+	I:C2748185
group	O
.	O

When	O
only	O
anti-HCV	O
/	O
HCV	O
RNA	I:C0855842
+	I:C0855842
serum	O
samples	I:C1550100
,	O
that	O
is	O
,	O
true	O
positives	O
,	O
were	O
considered	O
,	O
the	O
sensitivities	O
were	O
98.3	O
%	O
and	O
100	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HCV	O
+	I:C2748185
group	O
and	O
91.6	O
%	O
and	O
94.8	O
%	O
for	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
,	O
respectively	O
,	O
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	B:C1257890
.	O

High	O
absorbance	B:C1268822
values	O
were	O
observed	O
among	O
those	O
presenting	O
with	O
HCV	O
RNA	I:C1868902
in	O
serum	O
and	O
low	O
HIV	O
viral	I:C1168369
load	I:C1168369
(	O
less	O
than	O
50	O
copies	O
/	O
mL	O
)	O
.	O

High	O
absorbance	O
values	O
were	O
observed	O
among	O
those	O
presenting	O
with	O
HCV	B:C1868902
RNA	I:C1868902
in	O
serum	O
and	O
low	O
HIV	O
viral	I:C1168369
load	I:C1168369
(	O
less	O
than	O
50	O
copies	O
/	O
mL	O
)	O
.	O

High	O
absorbance	O
values	O
were	O
observed	O
among	O
those	O
presenting	O
with	O
HCV	O
RNA	I:C1868902
in	O
serum	B:C0229671
and	O
low	O
HIV	O
viral	I:C1168369
load	I:C1168369
(	O
less	O
than	O
50	O
copies	O
/	O
mL	O
)	O
.	O

High	O
absorbance	O
values	O
were	O
observed	O
among	O
those	O
presenting	O
with	O
HCV	O
RNA	I:C1868902
in	O
serum	O
and	O
low	O
HIV	B:C1168369
viral	I:C1168369
load	I:C1168369
(	O
less	O
than	O
50	O
copies	O
/	O
mL	O
)	O
.	O

In	O
conclusion	O
,	O
dried	B:C3830395
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
samples	I:C0438730
could	O
be	O
used	O
for	O
anti-HCV	O
detection	O
,	O
particularly	O
to	O
identify	O
active	O
HCV	O
cases	O
,	O
but	O
low	O
sensitivity	O
was	O
observed	O
for	O
anti-HCV	O
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

In	O
conclusion	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	B:C0438730
samples	I:C0438730
could	O
be	O
used	O
for	O
anti-HCV	O
detection	O
,	O
particularly	O
to	O
identify	O
active	O
HCV	O
cases	O
,	O
but	O
low	O
sensitivity	O
was	O
observed	O
for	O
anti-HCV	O
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

In	O
conclusion	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
samples	I:C0438730
could	O
be	O
used	O
for	O
anti-HCV	B:C0166049
detection	O
,	O
particularly	O
to	O
identify	O
active	O
HCV	O
cases	O
,	O
but	O
low	O
sensitivity	O
was	O
observed	O
for	O
anti-HCV	O
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

In	O
conclusion	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
samples	I:C0438730
could	O
be	O
used	O
for	O
anti-HCV	O
detection	B:C1511790
,	O
particularly	O
to	O
identify	O
active	O
HCV	O
cases	O
,	O
but	O
low	O
sensitivity	O
was	O
observed	O
for	O
anti-HCV	O
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

In	O
conclusion	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
samples	I:C0438730
could	O
be	O
used	O
for	O
anti-HCV	O
detection	O
,	O
particularly	O
to	O
identify	O
active	O
HCV	B:C4288963
cases	O
,	O
but	O
low	O
sensitivity	O
was	O
observed	O
for	O
anti-HCV	O
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

In	O
conclusion	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
samples	I:C0438730
could	O
be	O
used	O
for	O
anti-HCV	O
detection	O
,	O
particularly	O
to	O
identify	O
active	O
HCV	O
cases	O
,	O
but	O
low	O
sensitivity	O
was	O
observed	O
for	O
anti-HCV	B:C0201487
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

In	O
conclusion	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
samples	I:C0438730
could	O
be	O
used	O
for	O
anti-HCV	O
detection	O
,	O
particularly	O
to	O
identify	O
active	O
HCV	O
cases	O
,	O
but	O
low	O
sensitivity	O
was	O
observed	O
for	O
anti-HCV	O
testing	I:C0201487
using	O
dried	B:C3830395
blood	I:C3830395
spots	I:C3830395
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	O
.	O

In	O
conclusion	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
samples	I:C0438730
could	O
be	O
used	O
for	O
anti-HCV	O
detection	O
,	O
particularly	O
to	O
identify	O
active	O
HCV	O
cases	O
,	O
but	O
low	O
sensitivity	O
was	O
observed	O
for	O
anti-HCV	O
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
in	O
the	O
HIV	B:C2748218
/	O
HCV	O
+	I:C2748185
group	O
.	O

In	O
conclusion	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
samples	I:C0438730
could	O
be	O
used	O
for	O
anti-HCV	O
detection	O
,	O
particularly	O
to	O
identify	O
active	O
HCV	O
cases	O
,	O
but	O
low	O
sensitivity	O
was	O
observed	O
for	O
anti-HCV	O
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
in	O
the	O
HIV	O
/	O
HCV	B:C2748185
+	I:C2748185
group	O
.	O

In	O
conclusion	O
,	O
dried	O
blood	I:C3830395
spots	I:C3830395
and	O
saliva	O
samples	I:C0438730
could	O
be	O
used	O
for	O
anti-HCV	O
detection	O
,	O
particularly	O
to	O
identify	O
active	O
HCV	O
cases	O
,	O
but	O
low	O
sensitivity	O
was	O
observed	O
for	O
anti-HCV	O
testing	I:C0201487
using	O
dried	O
blood	I:C3830395
spots	I:C3830395
in	O
the	O
HIV	O
/	O
HCV	O
+	I:C2748185
group	B:C1257890
.	O

